Background: Post-transplant diabetes mellitus (PTDM) is a complication of kidney transplantation, but the impact of early hyperglycemia (EH) remains unclear. This study aimed to assess the incidence of PTDM in kidney transplant recipients (KTRs) who experienced EH compared to those who do not at 6 months post-transplant. Methods: A single-center, retrospective cohort study was conducted in adults who underwent kidney transplantation from 1 January 2019 to 25 May 2022. KTRs who developed EH were compared against those who did not. Results: The primary outcome was the difference in incidence of PTDM at 6 months. Secondary outcomes included rehospitalizations and infections within 6 months and PTDM, renal function, cardiovascular events, and graft and patient survival within 12 months. Two hundred and seventy-nine KTRs (EH, n = 204 vs. comparator, n = 75) were included. There were higher incidences of PTDM in the EH group compared to the comparator group at 6 months (11% vs. 1.4%, p = 0.012) and 12 months post-transplant (18.5% vs. 5.5%, p = 0.007). KTRs with EH had 8.9 times greater odds of developing PTDM (OR 8.9; 95% 1.2–67.3, p = 0.03) at 6 months. There was no significant difference found in other secondary outcomes. Conclusions: KTRs with EH had an increased incidence of developing PTDM.
5 February 2026 in AACE Endocrinology and Diabetes
Primary aldosteronism (PA) is associated with increased cardiovascular risk and accounts for up to 30% of resistant hypertension cases, but less than 2% of true PA cases are diagnosed. The aldosterone-to-renin ratio (ARR) is the most common screening tool but is often misinterpreted due to failure to assess aldosterone and renin separately. Appropriate screening should be conducted off mineralocorticoid antagonists and serum potassium should be within normal limits on the day of testing. The aim of this study was to determine rates of appropriate PA screening and management in primary care. Adults newly established between 2021 and 2024 with indications for PA screening including resistant hypertension, hypertension on ≥4 medications or 3 medications with blood pressure > 130/80 mmHg, or hypertension with atrial fibrillation, adrenal adenoma, or hypokalemia were included. We assessed whether patients underwent renin and aldosterone testing, if testing occurred under appropriate conditions, and whether results were interpreted correctly. A total of 312 patients were indicated for PA screening primarily due to being on 3 antihypertensives with uncontrolled blood pressure (35.3%) or ≥4 antihypertensives (42.9%). Twelve patients (3.8%) were screened for PA, and 5 (41.7%) of those patients were screened appropriately. All screenings were interpreted as negative, yet 4 patients had true positive results. This study was limited to new patient encounters within a single internal medicine clinic and only followed patients for up to 12 months. PA remains underdiagnosed and mismanaged in primary care. Findings highlight the need for better provider education, awareness, and standardized protocols to improve detection and treatment for PA.
9 March 2026 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy